Skip to main content
Category

Research

MEDPAGE TODAY
ResearchTreatments

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

*October 2022* RESULTS: As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all…
laurabbook@gmail.com
December 11, 2022
Onc Live
ResearchTreatments

Inroads to Targeting HER2-Mutant Lung Cancer Begin Taking Shape

*October 2022* Targeted treatment options for patients with HER2-mutant non–small cell lung cancer (NSCLC) have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic. Three classes of agents have demonstrated efficacy in patients with HER2-mutant disease: tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and…
laurabbook@gmail.com
December 11, 2022
ResearchTreatments

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

*September 2022* The clinical significance of gene fusions detected by DNA-based next generation sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer. By studying EGFR inhibitor-resistant patients treated with a combination of an EGFR inhibitor and a drug targeting the putative…
laurabbook@gmail.com
December 11, 2022
ResearchTreatments

Living Room Recap – Options and Next Steps If Your Lung Cancer Becomes Resistant to Your Course of Treatment

*October 2022* What happens when your cancer becomes resistant to your course of treatment and progresses? Dr. David Gandara, professor emeritus and co-director of UC Davis Comprehensive Cancer Center’s Center for Experimental Therapeutics, discussed a number of options. The good news is that it turns out there’s a lot that…
laurabbook@gmail.com
December 11, 2022